Basilea Pharmaceutica Ltd. announced that it has entered into a licensing agreement with the U.S.-based company, Fox Chase Chemical Diversity Center Inc. (FCCDC), for a preclinical program on novel first-in-class broad spectrum antifungals with activity against difficult-to-treat mold infections. Under the terms of the agreement, Basilea is granted an exclusive worldwide license to FCCDC's antifungal program. FCCDC receives an undisclosed upfront payment and is eligible for further payments, upon the achievement of predefined development, regulatory and commercial milestones, as well as for tiered royalties on net sales.

This transaction has no impact on Basilea's financial guidance for 2022, provided on February 15, 2022.